1. Home
  2. BOLD vs CASI Comparison

BOLD vs CASI Comparison

Compare BOLD & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • CASI
  • Stock Information
  • Founded
  • BOLD 2018
  • CASI 1991
  • Country
  • BOLD United States
  • CASI China
  • Employees
  • BOLD N/A
  • CASI N/A
  • Industry
  • BOLD
  • CASI Biotechnology: Pharmaceutical Preparations
  • Sector
  • BOLD
  • CASI Health Care
  • Exchange
  • BOLD Nasdaq
  • CASI Nasdaq
  • Market Cap
  • BOLD 24.4M
  • CASI 20.5M
  • IPO Year
  • BOLD 2024
  • CASI 1996
  • Fundamental
  • Price
  • BOLD $1.19
  • CASI $1.52
  • Analyst Decision
  • BOLD Buy
  • CASI Strong Buy
  • Analyst Count
  • BOLD 3
  • CASI 1
  • Target Price
  • BOLD $4.00
  • CASI $4.00
  • AVG Volume (30 Days)
  • BOLD 105.5K
  • CASI 78.7K
  • Earning Date
  • BOLD 08-11-2025
  • CASI 08-15-2025
  • Dividend Yield
  • BOLD N/A
  • CASI N/A
  • EPS Growth
  • BOLD N/A
  • CASI N/A
  • EPS
  • BOLD N/A
  • CASI N/A
  • Revenue
  • BOLD N/A
  • CASI $31,368,000.00
  • Revenue This Year
  • BOLD N/A
  • CASI N/A
  • Revenue Next Year
  • BOLD N/A
  • CASI N/A
  • P/E Ratio
  • BOLD N/A
  • CASI N/A
  • Revenue Growth
  • BOLD N/A
  • CASI 8.39
  • 52 Week Low
  • BOLD $1.00
  • CASI $1.09
  • 52 Week High
  • BOLD $4.72
  • CASI $7.67
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • CASI 55.28
  • Support Level
  • BOLD N/A
  • CASI $1.21
  • Resistance Level
  • BOLD N/A
  • CASI $1.44
  • Average True Range (ATR)
  • BOLD 0.00
  • CASI 0.12
  • MACD
  • BOLD 0.00
  • CASI 0.04
  • Stochastic Oscillator
  • BOLD 0.00
  • CASI 55.36

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Share on Social Networks: